Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and adaptor protein crucial in non-small-cell lung cancer (NSCLC).
• The role of CBL in regulating MET signaling in NSCLC remains to be fully elucidated.

Purpose of the Study:

• To investigate if MET is a direct target of CBL.
• To determine if MET is enhanced in CBL-altered NSCLC.
• To assess the therapeutic potential of targeting MET in CBL-mutant NSCLC.

Main Methods:

• Comparative analysis of MET expression and ubiquitination in CBL wildtype versus mutant NSCLC cells.
• Assessment of cellular response to MET inhibitor SU11274 in CBL-altered cells.
• Evaluation of phospho-kinome alterations upon CBL knockdown.
• Investigating the effect of CBL knockdown on erlotinib-resistant H1975 cells.

Main Results:

• CBL mutant NSCLC cells exhibit lower MET expression and reduced MET ubiquitination compared to wildtype cells.
• CBL mutant cells show increased sensitivity to the MET inhibitor SU11274.
• Knockdown of CBL enhances NSCLC cell motility and colony formation, effects reversed by SU11274.
• Decreased phosphorylation in MET, paxillin, EPHA2, and VEGFR pathways was observed.
• CBL knockdown sensitized erlotinib-resistant H1975 cells to MET inhibition.

Conclusions:

• CBL regulates MET stability and activity in NSCLC.
• CBL alterations are associated with enhanced MET signaling.
• CBL status serves as a predictive biomarker for MET-targeted therapy efficacy in NSCLC.